Cipla strengthens US portfolio with the launch of generic Saxenda® (Liraglutide Injection) for weight management therapy
PR Newswire —
Partner Orbicular receives ANDA approval from USFDA MUMBAI, India and WARREN, N.J., Feb. 27, 2026 /PRNewswire/ -- Cipla USA Inc. the wholly owned subsidiary of Cipla Limited(BSE: 500087; NSE: CIPLA; and hereafter referred to as "Cipla") today announced the launch of Liraglutide Injection,...